Valuation: BIONET Corp.

Market Cap 3.03B 93.9M 82.31M 76.08M 69.97M 132M 9.06B 134M 910M 357M 4.43B 353M 345M 15.26B P/E 2024
48.2x
P/E 2025 102x
Enterprise Value 1.75B 54.14M 47.45M 43.86M 40.34M 76.11M 5.22B 77.33M 524M 206M 2.55B 203M 199M 8.8B EV / Sales 2024
2.09x
EV / Sales 2025 3.17x
Free-Float
77.12%
Yield 2024
1.78%
Yield 2025 0.84%
1 day-0.82%
1 week-9.32%
Current month-10.93%
1 month-10.00%
3 months-24.15%
6 months-44.68%
Current year-41.74%
1 week 60
Extreme 60
67.3
1 month 60
Extreme 60
73.8
Current year 60
Extreme 60
118
1 year 60
Extreme 60
118
3 years 51.92
Extreme 51.9178
162.01
5 years 32.78
Extreme 32.7754
162.01
10 years 20.08
Extreme 20.0761
162.01
Manager TitleAgeSince
Chief Executive Officer - 31/08/2006
Director of Finance/CFO - 22/03/2018
Director TitleAgeSince
Chairman - 31/07/2000
Director/Board Member - 10/04/2003
Director/Board Member 77 20/11/2006
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-9.32%-12.35%-3.47% 94.38M
-0.49%-4.01%-0.84%+2.28% 49.18B
-3.10%-1.94%+370.99%+572.60% 39.58B
-0.46%+2.18%+5.44%+61.01% 34.69B
-1.14%-1.76%+26.94%-9.93% 34.42B
-1.82%-1.43%+0.52%+31.85% 27.11B
-3.54%-5.08% - - 16.21B
-1.82%-0.43%+69.28%+113.82% 15.36B
+1.17%+2.30%+15.87%+18.26% 14.05B
-2.25%+0.05%+15.77%-32.83% 13.02B
Average -1.43%-1.33%+54.62%+83.73% 24.37B
Weighted average by Cap. -1.43%-1.02%+75.88%+118.63%

Financials

2024 2025
Net sales 1.22B 37.83M 33.16M 30.65M 28.19M 53.19M 3.65B 54.04M 366M 144M 1.78B 142M 139M 6.15B 1.24B 38.28M 33.55M 31.01M 28.52M 53.82M 3.69B 54.68M 371M 145M 1.81B 144M 141M 6.22B
Net income 83.7M 2.59M 2.27M 2.1M 1.93M 3.64M 250M 3.7M 25.1M 9.84M 122M 9.73M 9.52M 421M 51.43M 1.59M 1.4M 1.29M 1.19M 2.24M 154M 2.27M 15.42M 6.05M 75.11M 5.98M 5.85M 259M
Net Debt -1.48B -45.82M -40.16M -37.12M -34.14M -64.42M -4.42B -65.46M -444M -174M -2.16B -172M -168M -7.45B -1.28B -39.77M -34.86M -32.22M -29.63M -55.91M -3.83B -56.81M -385M -151M -1.88B -149M -146M -6.46B
Logo BIONET Corp.
BIONET CORP. is a Taiwan-based company principally engaged in the storage and application of hematopoietic stem cells. The Company’s main products include umbilical cord blood stem cells, mesenchymal stem cells, adult peripheral blood stem cells and others. The Company also provides precision medical application, prenatal testing and genetic testing services. The Company operates its businesses mainly in domestic market.
Employees
-
Date Price Change Volume
20/07/26 NT$60.30 -0.82% 389,699
17/07/26 NT$60.80 -4.70% 494,260
16/07/26 NT$63.80 -1.85% 113,778
15/07/26 NT$65.00 +1.72% 118,942
14/07/26 NT$63.90 -3.91% 335,919
  1. Stock Market
  2. Stocks
  3. 1784 Stock